The National First Province Consumables Centralized Procurement Distrust Rating Index Released

On February 10, the Xinjiang Uygur Autonomous Region Medical Security Bureau issued a notice on printing and distributing the "Indicators for Dishonest Collection of Centralized Procurement and Supply of Medicines and Medical Consumables in Xinjiang Uygur Autonomous Region (Trial)" ( hereinafter referred to as the Notice)
.
According to the "Discretionary Benchmarks for Pharmaceutical Prices and Recruitment and Procurement Credit Ratings (2020 Edition)", the untrustworthiness of major companies in the local bidding and procurement market is rated as "average", "moderate", "serious" and "extremely serious"
.
For enterprises rated as "serious" or "extremely serious" for dishonesty, in addition to warnings and warnings, they will also restrict or suspend the qualifications of all drugs and medical consumables to be listed on the Internet, bid or distribute, and are strictly prohibited from entering the market
.
So, which breaches of trust will be rated as "serious" and "extremely serious"? Details are included in this announcement
.
It can be seen that problems such as enterprises cutting off supplies without justifiable reasons and low distribution rates are the focus of the collection indicators for dishonesty
.
Untrustworthy Collection Indicators for Centralized Procurement and Supply of Medicines and Medical Consumables in Xinjiang Uygur Autonomous Region (Trial) 1.
Untrustworthy Collection of Centralized Procurement and Supply of Medicines in All Coordinated Areas 1.
The company involved refuses to perform the tripartite agreement without justifiable reasons, resulting in abnormal supply, and fails to notify the centralized purchasing agency and purchasing unit 1 month in advance, but does not affect the order of clinical diagnosis and treatment
.
2.
The monthly "3-day delivery rate" of the drugs or medical consumables involved in a purchase year is less than 40%, and the monthly "3-day delivery rate" = delivery within 3 days after the company receives the hospital's drug or medical consumables orders within the month Amount ÷ the monthly hospital order amount × 100% (the amount sent and the amount of the order are subject to the data recorded by the autonomous region's centralized procurement platform)
.
3.
The supply of drugs or medical consumables involved is less than 3 times in a procurement year (referring to the local medical institution reporting or complaining about the abnormal supply and the situation is true)
.
4.
The enterprise involved is in short supply or abnormal due to subjective reasons, and was inquired, investigated, interviewed, admonished, or inspected by the medical security department in the overall planning area, but shied away or refused to cooperate
.
(2) If one of the following circumstances is met, the untrustworthiness rating is rated as "moderate" 1.
The enterprise involved refuses to perform the tripartite agreement without justifiable reasons, resulting in a cut-off of supply, and fails to notify the centralized procurement agency or procurement unit 1 month in advance, but does not The order of clinical diagnosis and treatment constitutes a certain impact (discontinued supply means that the selected distribution company has 0 stocks of drugs or medical consumables for 7 consecutive days or the medical institution has not responded to the order twice in a row)
.
2.
The enterprises involved have accumulated more than 5 times of "general" dishonest acts within the overall planning area in the past three years (if multiple drugs or medical consumables are involved in the same case, the number of dishonest acts shall be counted separately, the same below)
.
3.
The supply of the drugs or medical consumables involved is cut off three or more times within a single procurement year
.
4.
The monthly "3-day delivery rate" of the drugs or medical consumables involved in the purchase year for 3 consecutive months is lower than 40%
.
5.
The enterprise involved in the above situation was caused by subjective reasons, and was inquired by the medical security department of the overall planning area, but it could not fully explain the reasonable reasons and refused to make corrections
.
(3) If one of the following circumstances is met, the untrustworthiness rating is rated as "serious" 1.
The enterprise involved refuses to perform the tripartite agreement without justifiable reasons, resulting in a cut off of supply, and fails to notify the centralized procurement agency and procurement unit 1 month in advance, and the clinical The order of diagnosis and treatment constitutes a serious impact, resulting in the lack of clinical treatment methods or the inability to implement clinical treatment plans, endangering the life safety of patients and other serious consequences
.
2.
The enterprise involved has committed "moderate" dishonesty more than three times within the overall planning area in the past three years
.
3.
The supply of the medicines or medical consumables involved has been interrupted for more than 3 consecutive months within a procurement year
.
4.
The company involved fails to complete the agreed purchase volume of the drugs or medical consumables involved within one procurement year.

.
5.
If the enterprise involved caused the above situation due to subjective reasons, after being inquired by the medical security department of the overall planning area, it was unable to fully explain the reason and refused to correct it
.
(4) If one of the following conditions is met, the untrustworthiness rating is rated as "extremely serious" 1.
The enterprise involved has accumulated more than three times of "serious" untrustworthiness within the overall planning area in the past three years
.
2.
The company involved fails to supply the drugs or medical consumables involved within one purchasing year
.
2.
Untrustworthy collection of centralized procurement and supply of medicines in the autonomous region (1) If one of the following conditions is met, the untrustworthiness rating is rated as "general" "General" dishonest behavior more than 3 times
.
2.
After the company involved was disclosed, interviewed, and inquired by the relevant departments of the autonomous region, there was no justifiable reason or rectification was not made on time
.
3.
Other acts that should be included in "general" dishonesty
.
(2) If one of the following conditions is met, the untrustworthiness rating is rated as "moderate" 1.
The enterprise involved has accumulated more than 5 "general" untrustworthy acts within the autonomous region (including the autonomous region level) in the past three years
.
2.
The enterprises involved are classified as "moderate" in the untrustworthiness rating by the overall planning area (including the autonomous region level)
.
3.
Other acts that should be listed as "moderate" dishonesty
.
(3) If one of the following conditions is met, the untrustworthiness rating shall be rated as "serious" 1.
The enterprise involved has committed "moderate" untrustworthy conduct more than 3 times in the past three years within the autonomous region (including the autonomous region level)
.
2.
The enterprise involved has been classified as "serious" by the overall planning area (including the autonomous region level)
.
3.
The company involved refuses to perform the tripartite agreement without justifiable reasons, which has a serious impact on the order of clinical diagnosis and treatment, resulting in the lack of clinical treatment methods or the inability to implement clinical treatment plans, and endangering the life safety of patients and other serious consequences
.
4.
Other acts that should be listed as "serious" dishonesty
.
(4) If one of the following conditions is met, the untrustworthiness rating is rated as "extremely serious" 1.
The enterprise involved has committed "serious" untrustworthy conduct more than 3 times in the past three years within the autonomous region (including the autonomous region level)
.
2.
The enterprises involved are classified as "especially serious" by the overall planning area (including the autonomous region level)
.
3.
Other acts that should be listed as "especially serious" dishonesty
.
However, it is not without opportunity for correction
.
Untrustworthy enterprises can take the initiative to repair the untrustworthy according to the norms, coordinate the regional medical security department, the autonomous region government service and the public resource trading center according to the corresponding relationship between the discretionary benchmark and the repair measures, timely confirm whether the repair items are effective, and reasonably adjust the untrustworthiness level
.
Dishonest recruiting, a group of machinery companies were named and notified Before this, many machinery companies across the country had been named and notified for their dishonesty behavior
.
Recently, the Guangxi Zhuang Autonomous Region Pharmaceutical Equipment Centralized Procurement Network has released the "Notice on Guangxi Zhuang Autonomous Region's Pharmaceutical Prices and Recruitment and Procurement Credit Rating Results (Phase 1)"
.
According to the "Notice", in the sunshine procurement of high-value medical consumables in Guangxi Zhuang Autonomous Region, 5 companies did not truthfully fill in the historical purchase prices, and there was a breach of trust
.
The pharmaceutical prices and untrustworthiness of recruiting and purchasing of these 5 companies were rated as "average"
.
Judging from the notice issued by Xinjiang this time, these five companies may still have the problem of not ensuring the stable supply of products after winning the bid
.
In September last year, the National Medical Insurance Bureau released the first issue of the "Severe" and "Extraordinarily Serious" Dishonesty Evaluation Results of Price Recruitment and Procurement Credit Evaluation.
Mainly related to bribery and confession
.
It is expected that in 2022, other regions will gradually standardize the collection indicators of dishonesty, and each pharmaceutical and equipment company should also take this opportunity to seize the opportunity to check and rectify itself, and refrain from stepping on thunder, so as not to affect the future development of the company itself.

.
National Medical Insurance Bureau: Focus on the "post-link" of consumables centralized procurement Judging from the notice issued by Xinjiang this time, the future focus of the National Medical Insurance Bureau must include the supply guarantee capability in the "post-link" of consumable centralized procurement
.
In April 2021, the Price Recruitment and Procurement Department of the National Medical Insurance Administration held a symposium for pharmaceutical distribution companies to discuss deepening the reform of centralized procurement of drugs and medical consumables, pharmaceutical circulation links, and supply guarantee capabilities
.
On February 11, at the State Council's regular briefing on the progress of the reform of centralized procurement of medicines and high-value medical consumables, officials also made it clear that they must adhere to the country's decision-making and deployment, and actively carry out the production and supply guarantee of the selected products
.
In order to ensure the supply of the winning products, China's medical insurance sector has also made many efforts
.
The Medical Insurance Bureau actively carries out the production dynamic monitoring of the national centralized procurement of medical devices, organizes the winning companies to submit the production, sales and inventory data of the centralized procurement of drugs on a monthly basis, dynamically grasps the production and supply situation, analyzes and judges in a timely manner, and ensures that the winning drugs can be stable in accordance with the agreement.
supply
.
In the face of enterprises, we will also timely understand and help coordinate and solve some problems encountered by enterprises in the process of production and operation, strengthen the guarantee of production factors, and ensure the stable production of selected varieties
.
In addition, the state is also promoting the construction of large-scale and intelligent production lines for centralized procurement of varieties
.
Support the advantageous selected enterprises to technically transform existing production lines or build new production lines, realize the continuity of the production process, maintain the consistency of product quality, and improve the level of production intelligence and production quality
.
Officials said that in the future, they will also urge enterprises to do a good job in the production and supply of selected varieties, and focus on tackling the shortcomings of the pharmaceutical industry to ensure a stable supply of selected drugs and high-value medical consumables
.